dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Grothey, Axel |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Wasan, Harpreet |
dc.contributor.author | Yoshino, Takayuki |
dc.contributor.author | Yaeger, Rona |
dc.date.accessioned | 2021-07-02T12:16:33Z |
dc.date.available | 2021-07-02T12:16:33Z |
dc.date.issued | 2021-02-01 |
dc.identifier.citation | Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/6118 |
dc.description | Càncer colorectal; Eficàcia i seguretat; Encorafenib més cetuximab |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;39(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Intestí gros - Càncer |
dc.subject | Medicaments antineoplàstics - Ús terapèutic - Eficàcia |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Treatment Outcome |
dc.subject.mesh | Colorectal Neoplasms |
dc.title | Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.20.02088 |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | resultado del tratamiento |
dc.subject.decs | neoplasias colorrectales |
dc.relation.publishversion | https://ascopubs.org/doi/10.1200/JCO.20.02088 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Grothey A] West Cancer Center, OneOncology, Germantown, TN. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Yaeger R] Memorial Sloan-Kettering Cancer Center, New York, NY. [Wasan H] Hammersmith Hospital, Department of Cancer Medicine, Imperial College London, London, United Kingdom. [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan |
dc.identifier.pmid | 33503393 |
dc.identifier.wos | 000635367200005 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |